
Jae Park
@jaeparkmd
ID: 739225830090543109
04-06-2016 22:42:27
34 Tweet
209 Takipçi
43 Takip Edilen

We’ll present our trial result of vemurafenib plus obinutuzumab for frontline HCL, abstract 43 this morning at #ASH21 #MSK Come and join! Fruitful collaboration with The Leukemia & Lymphoma Society HCLFoundation. Thanks to my co-investigators!